11 March 2024
Aptamer
Group plc
("Aptamer" or the "Company")
Aptamer Group progresses
partnership with Unilever plc ("Unilever")
- Successful Optimer® development for fast-moving
consumer goods
- The
partnership has advanced to warrant the patenting of the new
binders
Aptamer Group plc (AIM: APTA), the developer of
novel Optimer® binders to enable innovation in
the life sciences industry, today announces the successful
progression of its long-standing development partnership with
Unilever for identification of Optimers capable of supporting the
development of novel fast moving consumer goods ("FMCG")
applications.
Following formation of a partnership
with Unilever in FY2023, Aptamer has successfully developed the
required Optimers and demonstrated their performance through
in-house assays. After being shipped to Unilever, the Optimers
delivered highly positive and reproducible results in their
laboratories, indicating their potential for use in downstream
products. In parallel, Aptamer has streamlined the Optimers to
improve their function and manufacturability and is working to
transfer these to Unilever for further evaluation.
Based on the successful progress of
this scientific work, Aptamer and Unilever are now drafting patent
applications to protect these developments and downstream
commercial applications.
Steve Hull, Chairman of Aptamer
Group, said: "We are delighted to support
our partners at Unilever with Optimer technology that is providing
novel solutions in multiple areas, now including fast-moving
consumer goods. Over the past two years, we have worked closely
with the team at Unilever, to develop successful binders and are
pleased to see the promising results the binders are delivering in
their laboratories, further validating our technology and
leadership position in the affinity ligand market. With such strong
results and the continued progression of this partnership, we are
pleased to begin patenting these binders and allow the next stage
of advances. I look forward to updating you on this project as it
develops."
- ENDS
-
For further information, please
contact:
Aptamer Group plc
Steve Hull
|
+44 (0) 1904 217 404
|
SPARK Advisory Partners Limited -
Nominated Adviser
Andrew Emmott / Mark Brady / Adam
Dawes
|
+44 (0) 20 3368 3550
|
Turner
Pope Investments
(TPI) Limited - Broker
James Pope /
Andrew Thacker
|
+44 (0) 20 3657 0050
|
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its proprietary
Optimer® platform to enable
new approaches in therapeutics, diagnostics, and research
applications. The Company strives to deliver transformational
solutions that meet the needs of life science researchers and
developers.
Optimer binders are oligonucleotide
affinity ligands that can function as an antibody alternative. The
global affinity ligand market is currently worth over US$170
billion.
Aptamer has successfully delivered
projects for a range of global pharma companies, diagnostic
development companies, and research institutes, covering multiple
application areas with the objective of establishing
royalty-bearing licenses.